Prevention of hepatitis B

Cold Spring Harb Perspect Med. 2015 Mar 2;5(3):a021493. doi: 10.1101/cshperspect.a021493.

Abstract

Hepatitis B virus (HBV) causes life-threatening liver disease. It is transmitted through a horizontal route or a mother-to-infant route, and the latter is the major route in endemic areas. Prevention of HBV infection by immunization is the best way to eliminate HBV-related diseases. The HBV vaccine is the first human vaccine using a viral antigen from infected persons, which is safe and effective. Either passive immunization by hepatitis B immunoglobulin (HBIG) or active immunization by HBV vaccine is effective, and a combination of both yields the best efficacy in preventing HBV infection. The impact of universal HBV immunization is huge, with 90%-95% effectiveness in preventing chronic HBV infection. It is the first cancer preventive vaccine with a protective efficacy against hepatocellular carcinoma (HCC) of ∼ 70%. Nevertheless, further effort is still needed to avoid vaccine failure and to increase the global coverage rate.

Publication types

  • Review

MeSH terms

  • Carcinoma, Hepatocellular / prevention & control*
  • Hepatitis B Vaccines / therapeutic use*
  • Hepatitis B, Chronic / prevention & control*
  • Humans
  • Immunoglobulins / therapeutic use*
  • Liver Neoplasms / prevention & control*
  • Vaccination

Substances

  • Hepatitis B Vaccines
  • Immunoglobulins
  • hepatitis B hyperimmune globulin